← Human Trials & Peer-Reviewed Studies
A randomized, double-blind, placebo-controlled, 12-week trial of vitamin D augmentation in major depressive disorder associated with vitamin D deficiency.
Plain-language guide to PMID 35843459 (2022): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 35843459
- Journal
- Journal of affective disorders
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Kumar PNS et al. (3 authors)
- DOI
- 10.1016/j.jad.2022.07.014
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
Randomized controlled trials (RCTs) of vitamin D (VitD) supplementation for depression have yielded inconsistent results.
The researchers conducted the first RCT of VitD supplementation with multipoint serum 25(OH)D assessments in major depressive disorder (MDD) patients with concurrent severe VitD deficiency.
Who Took Part
PubMed indexes the participants as adults.
Patients were rated at baseline and at the end of weeks 4, 8, and 12.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
Serum 25(OH)D was estimated at baseline, week 8, and week 12.
What Was Measured
The researchers conducted the first RCT of VitD supplementation with multipoint serum 25(OH)D assessments in major depressive disorder (MDD) patients with concurrent severe VitD deficiency.
Topics PubMed links to this paper include Cholecalciferol, Major Depressive Disorder, Dietary Supplements, Vitamin D, Vitamin D Deficiency and Vitamins.
Author keywords: Antidepressant, Escitalopram, Randomized controlled trial and Vitamin D supplementation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (Journal of affective disorders), a journal based in Netherlands.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.